Singapore, Dec. 23 -- The International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA), together with four partner institutions, have signed a Memorandum of Understanding (MoU) to establish and manage a collaborative network for clinical trial sample analysis. The agreement is designed to strengthen Korea's capacity to respond swiftly and effectively to future pandemics.

The MoU brings together leading institutions with Biosafety Level 3 (BSL-3) facilities, aiming to expand Good Clinical Laboratory Practice (GCLP) certification, build a joint validation system, and strengthen the reliability of vaccine clinical trial analyses. In addition to IVI and KDCA, partners include the National Medical Center, t...